EXHIBIT 10.2
SECURITIES PURCHASE
AGREEMENT
This Securities Purchase Agreement
(this “ Agreement ”) is dated as of
July 29, 2009, between Inovio Biomedical Corporation, a
Delaware corporation (the “ Company ”), and each
purchaser identified on the signature pages hereto (each,
including its successors and assigns, a “ Purchaser
” and collectively the “ Purchasers
”).
WHEREAS, subject to the terms and
conditions set forth in this Agreement and pursuant to an effective
registration statement under the Securities Act of 1933, as amended
(the “ Securities Act ”), the Company desires to
issue and sell to each Purchaser, and each Purchaser, severally and
not jointly, desires to purchase from the Company, securities of
the Company as more fully described in this Agreement.
NOW, THEREFORE, IN CONSIDERATION of
the mutual covenants contained in this Agreement, and for other
good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as
follows:
ARTICLE I.
DEFINITIONS
1.1
Definitions
. In
addition to the terms defined elsewhere in this Agreement, for all
purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:
“
Action ” shall have the meaning ascribed to such term
in Section 3.1(j).
“ Affiliate ”
means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under
Rule 405 under the Securities Act.
“ Board of Directors
” means the board of directors of the Company.
“ Business Day ”
means any day except any Saturday, any Sunday, any day which is a
federal legal holiday in the United States or any day on which
banking institutions in the State of New York are authorized or
required by law or other governmental action to close.
“ Closing ” means
the closing of the purchase and sale of the Securities pursuant to
Section 2.1.
“ Closing Date ”
means the Trading Day on which all of the Transaction Documents
have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchasers’
obligations to pay the Subscription Amount and (ii) the
Company’s obligations to deliver the Securities, in each
case, have been satisfied or waived.
“ Commission ”
means the United States Securities and Exchange
Commission.
1
“ Common Stock ”
means the common stock of the Company, par value $0.001 per share,
and any other class of securities into which such securities may
hereafter be reclassified or changed.
“ Common Stock
Equivalents ” means any securities of the Company or the
Subsidiaries which would entitle the holder thereof to acquire at
any time Common Stock, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, Common
Stock.
“ Company Counsel
” means Morrison & Foerster LLP, with offices
located at 12531 High Bluff Drive, San Diego, CA 92130.
“ Disclosure Schedules
” means the Disclosure Schedules of the Company delivered
concurrently herewith.
“ Evaluation Date
” shall have the meaning ascribed to such term in
Section 3.1(r).
“ Exchange Act ”
means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder.
“ Exempt Issuance
” means the issuance of (a) shares of Common Stock or options
to employees, officers or directors of the Company pursuant to any
stock or option plan duly adopted for such purpose, by a majority
of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established
for such purpose, (b) securities upon the exercise or exchange of
or conversion of any Securities issued hereunder and/or other
securities exercisable or exchangeable for or convertible into
shares of Common Stock issued and outstanding on the date of this
Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such
securities or to decrease the exercise price, exchange price or
conversion price of such securities, and (c) securities issued
pursuant to acquisitions or strategic transactions approved by a
majority of the disinterested directors of the Company, provided
that any such issuance shall only be to a Person (or to the
equityholders of a Person) which is, itself or through its
subsidiaries, an operating company or an asset in a business
synergistic with the business of the Company and shall provide to
the Company additional benefits in addition to the investment of
funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or
to an entity whose primary business is investing in
securities.
“ GAAP ” shall
have the meaning ascribed to such term in
Section 3.1(h).
“ Indebtedness ”
shall have the meaning ascribed to such term in
Section 3.1(z).
“ Intellectual Property
Rights ” shall have the meaning ascribed to such term in
Section 3.1(o).
“ Liens ” means a
lien, charge, security interest, encumbrance, right of first
refusal, preemptive right or other restriction.
“ Material Adverse
Effect ” shall have the meaning assigned to such term in
Section 3.1(b).
“ Material Permits
” shall have the meaning ascribed to such term in
Section 3.1(m).
“ Per Share Purchase
Price ” equals $2.70, subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and
other similar transactions of the Common Stock that occur after the
date of this Agreement.
“ Person ” means
an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“ Proceeding ”
means an action, claim, suit, investigation or proceeding
(including, without limitation, an informal investigation or
partial proceeding, such as a deposition), whether commenced or
threatened.
2
“ Prospectus ”
means the final prospectus filed for the Registration
Statement.
“ Prospectus Supplement
” means the supplement to the Prospectus complying with
Rule 424(b) of the Securities Act that is filed with the
Commission and delivered by the Company to each Purchaser at the
Closing.
“ Purchaser Party
” shall have the meaning ascribed to such term in
Section 4.8.
“ Registration
Statement ” means the effective registration statement
with Commission file No. 333-160123 which registers the sale
of the Shares, the Warrants and the Warrant Shares to the
Purchasers.
“ Required Approvals
” shall have the meaning ascribed to such term in
Section 3.1(e).
“ Rule 144 ”
means Rule 144 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the
Commission having substantially the same effect as such
Rule.
“ Rule 424 ”
means Rule 424 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter
adopted by the Commission having substantially the same purpose and
effect as such Rule.
“ SEC Reports ”
shall have the meaning ascribed to such term in
Section 3.1(h).
“ Securities ”
means the Shares, the Warrants and the Warrant Shares.
“ Securities Act
” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.
“ Shares ” means
the shares of Common Stock issued or issuable to each Purchaser
pursuant to this Agreement.
“ Short Sales ”
means all “short sales” as defined in Rule 200 of
Regulation SHO under the Exchange Act (but shall not be deemed to
include the location and/or reservation of borrowable shares of
Common Stock).
“ Subscription Amount
” means, as to each Purchaser, the aggregate amount to be
paid for Shares and Warrants purchased hereunder as specified below
such Purchaser’s name on the signature page of this
Agreement and next to the heading “Subscription
Amount,” in United States dollars and in immediately
available funds.
“ Subsidiary ”
means any subsidiary of the Company as set forth on Schedule
3.1(a) , and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the
date hereof.
3
“ Trading Day ”
means a day on which the principal Trading Market is open for
trading.
“ Trading Market
” means any of the following markets or exchanges on which
the Common Stock is listed or quoted for trading on the date in
question: the NYSE AMEX, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange or the OTC Bulletin Board (or any successors to any of the
foregoing).
“ Transaction Documents
” means this Agreement, the Warrants and any other documents
or agreements executed in connection with the transactions
contemplated hereunder.
“ Transfer Agent
” means Computershare, the current transfer agent of the
Company, with a mailing address of 3rd Floor — 510
Burrard St., Vancouver, BC V6C 3B9 and a facsimile number of
,
and any successor transfer agent of the Company.
“ Warrants ”
means, collectively, the Common Stock Greenshoe Warrants delivered
to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, which Warrants shall be
exercisable beginning 6 months following the Closing Date and have
a term of exercise equal to 6 months following their initial
exercise date, in the form of Exhibit A attached
hereto.
“ Warrant Shares
” means the shares of Common Stock issuable upon exercise of
the Warrants.
“ WS ” means
Weinstein Smith LLP with offices located at 420 Lexington Avenue,
Suite 2620, New York, New York 10170-0002.
ARTICLE II.
PURCHASE AND SALE
2.1
Closing
. On the
Closing Date, upon the terms and subject to the conditions set
forth herein, substantially concurrent with the execution and
delivery of this Agreement by the parties hereto, the Company
agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $30,000,000 of
Shares and Warrants. Each Purchaser shall deliver to the
Company, via wire transfer or a certified check of immediately
available funds equal to such Purchaser’s Subscription Amount
as set forth on the signature page hereto executed by such
Purchaser and the Company shall deliver to each Purchaser its
respective Shares and a Warrant as determined pursuant to
Section 2.2(a), and the Company and each Purchaser shall
deliver the other items set forth in Section 2.2 deliverable
at the Closing. Upon satisfaction of the covenants and
conditions set forth in Sections 2.2 and 2.3, the Closing shall
occur at the offices of WS or such other location as the parties
shall mutually agree.
4
2.2
Deliveries
.
(a)
On or prior to
the Closing Date, the Company shall deliver or cause to be
delivered to each Purchaser the following:
(i)
this Agreement
duly executed by the Company;
(ii)
a legal opinion
of Company Counsel, substantially in the form of
Exhibit B attached hereto;
(iii)
a copy of the
irrevocable instructions to the Company’s transfer agent
instructing the transfer agent to deliver via the Depository Trust
Company Deposit Withdrawal Agent Commission System (“
DWAC ”) Shares equal to such Purchaser’s
Subscription Amount divided by the Per Share Purchase Price,
registered in the name of such Purchaser;
(iv)
a Warrant
registered in the name of such Purchaser to purchase up to a number
of shares of Common Stock equal to 25% of such Purchaser’s
Shares, with an exercise price equal to $3.50, subject to
adjustment therein (such Warrant certificate may be delivered
within three Trading Days of the Closing Date); and
(v)
the Prospectus
and Prospectus Supplement (which may be delivered in accordance
with Rule 172 under the Securities Act).
(b)
On or prior to
the Closing Date, each Purchaser shall deliver or cause to be
delivered to the Company the following:
(i)
this Agreement
duly executed by such Purchaser; and
(ii)
such
Purchaser’s Subscription Amount by wire transfer to the
account as specified in writing by the Company.
2.3
Closing
Conditions .
(a)
The obligations
of the Company hereunder in connection with the Closing are subject
to the following conditions being met:
(i)
the accuracy in
all material respects on the Closing Date of the representations
and warranties of the Purchasers contained herein (unless as of a
specific date therein);
(ii)
all obligations,
covenants and agreements of each Purchaser required to be performed
at or prior to the Closing Date shall have been performed;
and
(iii)
the delivery by
each Purchaser of the items set forth in
Section 2.2(b) of this Agreement.
(b)
The respective
obligations of the Purchasers hereunder in connection with the
Closing are subject to the following conditions being
met:
5
(i)
the accuracy in
all material respects when made and on the Closing Date of the
representations and warranties of the Company contained herein
(unless as of a specific date therein);
(ii)
all obligations,
covenants and agreements of the Company required to be performed at
or prior to the Closing Date shall have been performed;
(iii)
the delivery by
the Company of the items set forth in Section 2.2(a) of
this Agreement;
(iv)
there shall have
been no Material Adverse Effect with respect to the Company since
the date hereof; and
(v)
from the date
hereof to the Closing Date, trading in the Common Stock shall not
have been suspended by the Commission or the Company’s
principal Trading Market (except for any suspension of trading of
limited duration agreed to by the Company, which suspension shall
be terminated prior to the Closing), and, at any time prior to the
Closing Date, trading in securities generally as reported by
Bloomberg L.P. shall not have been suspended or limited, or minimum
prices shall not have been established on securities whose trades
are reported by such service, or on any Trading Market, nor shall a
banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any
material outbreak or escalation of hostilities or other national or
international calamity of such magnitude in its effect on, or any
material adverse change in, any financial market which, in each
case, in the reasonable judgment of each Purchaser, makes it
impracticable or inadvisable to purchase the Securities at the
Closing.
ARTICLE III.
REPRESENTATIONS AND WARRANTIES
3.1
Representations and
Warranties of the Company . Except as set forth
in the Disclosure Schedules, which Disclosure Schedules shall be
deemed a part hereof and shall qualify any representation or
otherwise made herein to the extent of the disclosure contained in
the corresponding section of the Disclosure Schedules, the Company
hereby makes the following representations and warranties to each
Purchaser:
(a)
Subsidiaries
. All of
the direct and indirect subsidiaries of the Company are set forth
on Schedule 3.1(a). The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each
Subsidiary free and clear of any Liens, and all of the issued and
outstanding shares of capital stock of each Subsidiary are validly
issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities.
If the Company has no subsidiaries, all other references to the
Subsidiaries or any of them in the Transaction Documents shall be
disregarded.
(b)
Organization
and Qualification . The Company and each
of the Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in
6
good standing
under the laws of the jurisdiction of its incorporation or
organization, with the requisite power and authority to own and use
its properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other
organizational or charter documents. Each of the Company and
the Subsidiaries is duly qualified to conduct business and is in
good standing as a foreign corporation or other entity in each
jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the
case may be, could not have or reasonably be expected to result in:
(i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material
adverse effect on the results of operations, assets, business or
financial condition of the Company and the Subsidiaries, taken as a
whole, or (iii) a material adverse effect on the
Company’s ability to perform in any material respect on a
timely basis its obligations under any Transaction Document (any of
(i), (ii) or (iii), a “ Material Adverse Effect
”) and no Proceeding has been instituted in any such
jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or
qualification.
(c)
Authorization;
Enforcement . The Company has the
requisite corporate power and authority to enter into and to
consummate the transactions contemplated by each of the Transaction
Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of each of the
Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and
no further action is required by the Company, the Board of
Directors or the Company’s stockholders in connection
therewith other than in connection with the Required
Approvals. Each Transaction Document to which it is a party
has been (or upon delivery will have been) duly executed by the
Company and, when delivered in accordance with the terms hereof and
thereof, will constitute the valid and binding obligation of the
Company enforceable against the Company in accordance with its
terms, except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by
applicable law.
(d)
No
Conflicts . The execution,
delivery and performance by the Company of the Transaction
Documents, the issuance and sale of the Securities and the
consummation by it of the transactions contemplated hereby and
thereby to which it is a party do not and will not
(i) conflict with or violate any provision of the
Company’s or any Subsidiary’s certificate or articles
of incorporation, bylaws or other organizational or charter
documents, or (ii) conflict with, or constitute a default (or
an event that with notice or lapse of time or both would become a
default) under, result in the creation of any Lien upon any of the
properties or assets of the Company or any Subsidiary, or give to
others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of,
any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or
other
7
understanding to
which the Company or any Subsidiary is a party or by which any
property or asset of the Company or any Subsidiary is bound or
affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is
subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a
Subsidiary is bound or affected; except in the case of each of
clauses (ii) and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.
(e)
Filings,
Consents and Approvals . The Company is not
required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any
court or other federal, state, local or other governmental
authority or other Person in connection with the execution,
delivery and performance by the Company of the Transaction
Documents, other than: (i) the filings required pursuant to
Section 4.4 of this Agreement, (ii) the filing with the
Commission of the Prospectus Supplement,
(iii) application(s) to each applicable Trading Market
for the listing of the Securities for trading thereon in the time
and manner required thereby and (iv) such filings as are
required to be made under applicable state securities laws
(collectively, the “ Required Approvals
”).
(f)
Issuance of
the Securities; Registration . The Securities are
duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly
issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company. The Warrant Shares, when issued in
accordance with the terms of the Warrants, will be validly issued,
fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Company has reserved from its duly
authorized capital stock the maximum number of shares of Common
Stock issuable pursuant to this Agreement and the Warrants. The
Company has prepared and filed the Registration Statement in
conformity with the requirements of the Securities Act, which
became effective on July 1, 2009 (the “ Effective
Date ”), including the Prospectus, and such amendments
and supplements thereto as may have been required to the date of
this Agreement. The Registration Statement is effective under
the Securities Act and no stop order preventing or suspending the
effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the
Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the
Commission. The Company, if required by the rules and
regulations of the Commission, proposes to file the Prospectus,
with the Commission pursuant to Rule 424(b). At the time
the Registration Statement and any amendments thereto became
effective, at the date of this Agreement and at the Closing Date,
the Registration Statement and any amendments thereto conformed and
will conform in all material respects to the requirements of the
Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements
therein not misleading; and the Prospectus and any amendments or
supplements thereto, at the time the Prospectus or any amendment or
supplement thereto was issued and at the Closing Date, conformed
and will conform in all material respects to the requirements of
the Securities Act and did not
8
and will not
contain an untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in
light of the circumstances under which they were made, not
misleading.
(g)
Capitalization
. The
capitalization of the Company is as set forth on Schedule
3.1(g) . The Company has not issued any capital stock
since its most recently filed periodic report under the Exchange
Act, other than pursuant to the exercise of employee stock options
under the Company’s stock option plans, the issuance of
shares of Common Stock to employees pursuant to the Company’s
employee stock purchase plans and pursuant to the conversion and/or
exercise of Common Stock Equivalents outstanding as of the date of
the most recently filed periodic report under the Exchange
Act. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate
in the transactions contemplated by the Transaction
Documents. Except as set forth on Schedule 3.1(g)
or as a result of the purchase and sale of the Securities,
there are no outstanding options, warrants, scrip rights to
subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or giving any Person any right
to subscribe for or acquire, any shares of Common Stock, or
contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or Common Stock
Equivalents. The issuance and sale of the Securities will not
obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Purchasers) and will not
result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange or reset price under any of such
securities. All of the outstanding shares of capital stock of the
Company are validly issued, fully paid and nonassessable, have been
issued in compliance with all federal and state securities laws,
and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase
securities. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the
issuance and sale of the Securities. There are no
stockholders agreements, voting agreements or other similar
agreements with respect to the Company’s capital stock to
which the Company is a party or, to the knowledge of the Company,
between or among any of the Company’s
stockholders.
(h)
SEC Reports;
Financial Statements . The Company has filed
all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and
the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, for the two years preceding the date hereof (or
such shorter period as the Company was required by law or
regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by
reference therein, together with the Prospectus and the Prospectus
Supplement, being collectively referred to herein as the “
SEC Reports ”) on a timely basis or has received a
valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of
their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Reports, when
filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary
in order to make
9
the statements
therein, in the light of the circumstances under which they were
made, not misleading. The Company has never been an issuer subject
to Rule 144(i) under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all
material respects with applicable accounting requirements and the
rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis during
the periods involved (“ GAAP ”), except as may
be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not
contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its
consolidated Subsidiaries as of and for the dates thereof and the
results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.
(i)
Material
Changes; Undisclosed Events, Liabilities or Developments
. Since the
date of the latest audited financial statements included within the
SEC Reports, except as specifically disclosed in a subsequent SEC
Report filed prior to the date hereof, (i) there has been no
event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued
expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be
reflected in the Company’s financial statements pursuant to
GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting,
(iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or
purchased, redeemed or made any agreements to purchase or redeem
any shares of its capital stock and (v) the Company has not
issued any equity securities to any officer, director or Affiliate,
except pursuant to existing Company stock option plans. The
Company does not have pending before the Commission any request for
confidential treatment of information. Except for the
issuance of the Securities contemplated by this Agreement or as set
forth on Schedule 3.1(i) , no event, liability, fact,
circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the
Company or its Subsidiaries or their respective business,
prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least 1
Trading Day prior to the date that this representation is
made.
(j)
Litigation
. There is
no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any
of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an
“ Action ”) which (i) adversely affects or
challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) could, if
there were an unfavorable decision, have or reasonably be expected
to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor any director or officer thereof, is or has
been the subject of any
10
Action involving
a claim of violation of or liability under federal or state
securities laws or a claim of breach of fiduciary duty. There
has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer
of the Company. The Commission has not issued any stop order
or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange
Act or the Securities Act.
(k)
Labor Relations . No material labor dispute exists or,
to the knowledge of the Company, is imminent with respect to any of
the employees of the Company, which could reasonably be expected to
result in a Material Adverse Effect. None of the
Company’s or its Subsidiaries’ employees is a member of
a union that relates to such employee’s relationship with the
Company or such Subsidiary, and neither the Company nor any of its
Subsidiaries is a party to a collective bargaining agreement, and
the Company and its Subsidiaries believe that their relationships
with their employees are good. No executive officer, to the
knowledge of the Company, is, or is now expected to be, in
violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or
non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and the
continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all U.S. federal, state,
local and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages
and hours, except where the failure to be in compliance could not,
individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.
(l)
Compliance . Neither the Company nor any Subsidiary:
(i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of
time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received
notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or
any of its properties is bound (whether or not such default or
violation has been waived), (ii) is in violation of any
judgment, decree or order of any court, arbitrator or governmental
body or (iii) is or has been in violation of any statute,
rule, ordinance or regulation of any governmental authority,
including without limitation all foreign, federal, state and local
laws applicable to its business and all such laws that affect the
environment, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.
(m)
Regulatory Permits . The Company and the Subsidiaries
possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities
necessary to conduct their respective businesses as described in
the SEC Reports, except where the failure to possess such permits
could not reasonably be expected to result in a Material Adverse
Effect (“ Material Permits ”), and
11
neither the
Company nor any Subsidiary has received any notice of proceedings
relating to the revocation or modification of any Material
Permit.
(n)
Title to Assets . The Company and the Subsidiaries
have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal
property owned by them that is material to the business of the
Company and the Subsidiaries, in each case free and clear of all
Liens, except for Liens as do not materially affect the value of
such property and do not materially interfere with the use made and
proposed to be made of such property by the Company and the
Subsidiaries and Liens for the payment of federal, state or other
taxes, the payment of which is neither delinquent nor subject to
penalties. Any real property and facilities held under lease
by the Company and the Subsidiaries are held by them under valid,
subsisting and enforceable leases with which the Company and the
Subsidiaries are in compliance.
(o)
Patents and Trademarks . The Company and the
Subsidiaries have, or have rights to use, all patents, patent
applications, trademarks, trademark applications, service marks,
trade names, trade secrets, inventions, copyrights, licenses and
other intellectual property rights and similar rights necessary or
material for use in connection with their respective businesses as
described in the SEC Reports and which the failure to so have could
have a Material Adverse Effect (collectively, the “
Intellectual Property Rights ”). Neither the
Company nor any Subsidiary has received a written notice that any
of the Intellectual Property Rights used by the Company or any
Subsidiary violates or infringes upon the rights of any
Person. To the knowledge of the Company, all such
Intellectual Property Rights are e
|